ABOUT US
We’re a European pharmaceutical company.
We’re different. We’re not original, nor are we generic. We stand on the boundary.
We compete with generic companies through our original approach, constant movement, search for
new indications and utilization of the best and most interesting molecules available.
Our main therapeutic area is gastroenterology, and our portfolio is made up mostly of prescription
medicine.
our visions and ambitions
We work on various innovations which have the potential to change the lives of millions of people. That is our vision, our ambition and our self-realization. We live through our work and we know we will be successful.
We are used to thinking differently than other companies. We think originally and try to see the underlying connections that remain hidden to most. We see the world as a fair of unexplored possibilities from which we choose only the best market opportunities.
We are creative and we love non-traditional solutions. Our standard is the non-standard.
We always look for different, extraordinary paths. Thinking out of the box is our philosophy.
We know how to set ourselves apart as the successful ones.
We draw inspiration from each other. We are open, strategic and analytical. We cut to the chase.
We want to realize innovations, especially those that require confidence and courage. That is simply what we enjoy the most.
LEADERSHIP
Ivan Daněk
Owner and Chief Executive Officer
Ivan Daněk is a visionary and a strategist of Innovan Pharma responsible for leading the company towards achieving its high ambitions and long-term strategic goals.
His core expertise is in Marketing strategy, Business Development, Portfolio Management,
Salesforce effectiveness, Research and Development.
Ivan served as CEO of PRO.MED.CS Praha a.s. in 2016 -2020 and as a Member of the Board in 2013 – 2020. He established PRO.MEDs new growth strategy containing portfolio evaluation and entering new business territories. He aimed the new company philosophy at out-of-the-box thinking and brought to PRO.MED many talented and efficient managers. He successfully rebuilt the PRO.MED main business department, Russian branch, including portfolio, marketing strategy and personnel composition in 2003-2015.
As a result of Ivan´s leadership, the company saw more than 10 times increase in net profit between 2008 and 2015 and almost 3 times increase in net profit in 2013-2019 with 1 billion Czech crowns in 2019. That’s how PRO.MED became the distinguished mid-size European company, attractive for business partners, investors and employees.
Ivan puts the best knowledge, experience and fresh ideas into his company.
“A person's greatest happiness is when he can live for what he is willing to die for." - Honoré De Balzac
CEO´S MESSAGE
We have great innovation in our portfolio and I am determined to make it happen.
Most innovations stay on the ice because managers don´t have the courage, companies don´t have resources, time or money to act, or it mostly doesn´t fit into their internal guidelines and rules. That´s why they don´t do it.
However, I am convinced that our innovation will help many people and even save lives!
It may be the best thing we can do in our life. That´s why we are the ones who are going to do it.
Furthermore, it is a feasible, proven and profitable business.
THERAPEUTIC AREAS
Irritable bowel syndrome (IBS)
Is a functional gastrointestinal disorder. It’s a chronical condition of the digestive system, a lifelong problem that needs long term management. Symptoms include cramping, abdominal pain, bloating, gas and diarrhea or constipation, or both.
“The cause is unknown, but we think we know it.”
Gastroesophageal reflux disease (GERD)
manifests by frequent backwash of stomach acid into the esophagus connecting mouth and stomach that irritates the lining of the esophagus. Symptoms include heartburn, chest pain, difficulty swallowing, regurgitation of food or sour liquid, sensation of a lump in the throat, sometimes cough. GERD is caused by the lower esophageal sphincter’s disfunction.
“Nobody cures sphincter’s disfunction. We do.”
Functional dyspepsia (FD)
is a chronic disorder manifesting by symptoms like pain, burning or discomfort in the upper abdomen, early feeling of fullness, bloating, belching and nausea.
“FD is often used when diagnosis is “I don’t know”. But we do.”
Inflammatory bowel disease (IBD)
is a condition of chronical inflammation of digestive tract, include Crohn´s disease and ulcerative colitis. Symptoms are diarrhea, rectal bleeding, abdominal pain, cramping, fatigue and weight loss. IBD can lead to the life-threatening complications. Current treatment is very expensive and exacting.
“We have a cheaper and safer one.”
Colorectal cancer (CRC)
is the most diagnosed cancers and its incidence rates still increase in all developed countries.
“We have the proven prevention.”
PARTNERSHIP
We cooperate with medical professionals from all around the globe. We constantly expand our knowledge and understanding of present issues in gastroenterology and other specialized therapeutic areas.
We strive for effective collaboration with health authorities and insurance companies.
We cooperate with local pharmaceutical experts from different countries in order to expand our localization.
We are open to cooperation with investors, especially those with similar ways of thinking, but always those with the same courage and ambition as us.
We provide both value and attractive, sustainable returns to our shareholders.
We are also considering a variety of collaborative forms, such as co-promotion, co-marketing, in-licence agreements or M&A.
We press for fair and ethical behaviour in all our activities, and we work according to relevant laws and with the utmost professional standards. We treat our partners with honour and respect, reward loyalty, honesty, entrepreneurial spirit and outstanding performance.
Northen & Eastern Europe
Bulgaria
Croatia
Czech Rep.
Denmark
Estonia
Finland
Hungary
Iceland
Latvia
Lithuania
Norway
Poland
Romania
Slovakia
Slovenia
Sweden
Western & Southern Europe
Austria
Belgium
Cyprus
France
Germany
Greece
Ireland
Italy
Luxembourg
Malta
Netherlands
Portugal
Spain
Switzerland
United Kingdom
Middle East & North Africa
Jordan
Morocco
Bahrain
Oman
Egypt
Israel
Algeria
Tunisia
Saudi Arabia
Kuwait
Qatar
United Arab Emirates
Asia
Cambodia
China
Indonesia
Malaysia
Philippines
Singapore
Thailand
Turkey
Vietnam
Business development
We are committed to growing an innovative, well-balanced product portfolio from in-house developments, in-licensing and selective acquisitions. With our in-house expertise and network of research partners, we are committed to developing new and more advanced treatments that can help gastroenterologists improve patient care.
We work with innovative companies and academic institutions that are engaged in the research of illnesses related to gastroenterology which have high medical unmet needs. We strive to contribute to the improvement of gastrointestinal disease management.
Whether you are a small company striving to commercialize its product, or a larger company looking to sell a part of their portfolio, our experienced team will provide you with commercial, regulatory and technology-transfer support, and will, at the same time, ensure a long and successful collaboration.
Innovan Pharma’ Business Development & Licensing and Research & Development team is comprised of experienced professionals with track records dealing with international pharmaceutical companies. Our structure provides the framework for a great variety of different deals and business models. Our team members guarantee the experience, know-how and motivation to develop, structure, negotiate and execute such deals in a timely manner.
Innovan Pharma does not disclose information about its pipeline to the general public.
CONTACT US
Innovan Pharma s.r.o.
The Flow Building Václavské náměstí
2132/47 Praha 1, 110 00
